| [1] Peng HL,Zhang GS,Gong FJ,et al. Fms-like tyrosine kinase (FLT) 3 and FLT3 internal tandem duplication in different types of adult leukemia:analysis of 147 patients[J]. Croat Med J,2008,49(5):650-669.[2] Thiede C,Koch S,Creutzig E,et al. Prevalence and prognostic impact of NPM1 mutations in 1 485 adult patients with acute myeloid leukemia (AML)[J]. Blood,2006,107(10):4011-4020.[3] Ruan M,Zhang L,Han C,et al. NPM1 and CEBPA mutations in pediatric cytogenetically normal acute myeloid leukemia[J]. Zhonghua Er Ke Za Zhi,2014,52(4):303-307.[4] Barragan E,Cervera J,Bolufer P,et al. Prognostic implications of Wilms'tumor gene (WT1) expression in patients with de novo acute myeloid leukemia[J]. Haematologica,2004,89(8):926-933.[5] Jourdan E,Boissel N,Chevret S,et al. Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia[J]. Blood,2013,121(12):2213-2223.[6] Whitman SP,Maharry K,Radmacher MD,et al. FLT3 internal tandem duplication associates with adverse outcome and gene- and microRNA-expression signatures in patients 60 years of age or older with primary cytogenetically normal acute myeloid leukemia:a cancer and leukemia group B study[J]. Blood,2010,116(18):3622-3626.[7] Jones RJ,Matsui WH,Smith BD. Cancer stem cells:are we missing the target?[J]. J Natl Cancer Inst,2004,96(8):583-585.[8] Huff CA,Matsui W,Smith BD,et al. The paradox of response and survival in cancer therapeutics[J]. Blood,2006,107(2):431-434.[9] Lapidot T,Sirard C,Vormoor J,et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice[J]. Nature,1994,367(6464):645-648.[10] Bonnet D,Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell[J]. Nat Med,1997,3(7):730-737.[11] Wang L,Gao L,Xu S,et al. FISH+CD34+ CD38- cells detected in newly diagnosed acute myeloid leukemia patients can predict the clinical outcome[J]. J Hematol Oncol,2013,6(1):85.[12] 张之南. 血液病诊断及疗效标准[M]. 2版. 北京:科学出版社,1998:168-218.[13] Guzman ML,Neering SJ,Upchurch D,et al. Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells[J]. Blood,2001,98(8):2301-2307.[14] She M,Niu X,Chen X,et al. Resistance of leukemic stem-like cells in AML cell line KG1a to natural killer cell-mediated cytotoxicity[J]. Cancer Lett,2012,318(2):173-179.[15] Ebinger M,Witte KE,Ahlers J,et al. High frequency of immature cells at diagnosis predicts high minimal residual disease level in childhood acute lymphoblastic leukemia[J]. Leuk Res,2010,34(9):1139-1142.[16] Long J,Liu S,Li K,et al. High proportion of CD34+/CD38-cells is positively correlated with poor prognosis in newly diagnosed childhood acute lymphoblastic leukemia[J]. Leuk Lymphoma,2014,55(3):611-617.[17] Witte KE,Ahlers J,Schafer I,et al. High proportion of leukemic stem cells at diagnosis is correlated with unfavorable prognosis in childhood acute myeloid leukemia[J]. Pediatr Hematol Oncol,2011,28(2):91-99.[18] van Rhenen A,Feller N,Kelder A,et al. High stem cell frequency in acute myeloid leukemia at diagnosis predicts high minimal residual disease and poor survival[J]. Clin Cancer Res,2005,11(18):6520-6527.[19] Zhang CP,Wei H,Wang HJ,et al. Proportion of CD34(+)CD38(-) cell population in bone marrow of patients with de novo AML as prognostic factor of complete remission at first course of induction chemotherapy [J]. Zhongguo Shi Yan Xue Ye Xue Za Zhi,2011,19(5):1268-1272.[20] Leung W,Pui CH,Coustan-Smith E,et al. Detectable minimal residual disease before hematopoietic cell transplantation is prognostic but does not preclude cure for children with very-high-risk leukemia[J]. Blood,2012,120(2):468-472.[21] Plesa A,Elhamri M,Clapisson G,et al. Higher percentage of CD34+ CD38- cells detected by multiparameter flow cytometry from leukapheresis products predicts unsustained complete remission in acute myeloid leukemia[J]. Leuk Lymphoma,2014,17(7):1-8.[22] Hoang VT,Zepeda-Moreno A,Ho AD. Identification of leukemia stem cells in acute myeloid leukemia and their clinical relevance[J]. Biotechnol J,2012,7(6):779-788.[23] Ravandi F,Estrov Z. Eradication of leukemia stem cells as a new goal of therapy in leukemia[J]. Clin Cancer Res,2006,12(2):340-344. |
